Report Highlights
The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028.
Report Includes
- 23 data tables and 54 additional tables
- An overview of the global market for cell and gene therapy
- Analysis of global market trends, featuring historical revenue data for 2020, 2021, and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market’s size and revenue growth prospects specific to cell and gene therapy, along with a market share analysis by therapy type, product, application, and geographic region
- An update on recent advances in vector biology, drug delivery technology and gene editing technologies such as CRISPR
- Coverage of novel therapeutic products and promising new technologies still in the development and testing stage, with as assessment of the probability that they will be commercialized successfully in the next five years
- Discussion on recent approvals, developments, emerging technologies, ESG, and an investment outlook
- Profiles of leading market participants, including Novartis, Vericel Corp., Gilead Sciences Inc., Pharmicell Co. Ltd., and Bristol-Myers Squibb Co.
Report Scope
The scope of this study encompasses an investigation of the cell and gene therapy market, which includes a detailed analysis of the market's drivers, challenges and opportunities. The report also covers market projections to 2028 and market shares of key companies. The report includes the company profiles of the key players with information about their business segments, financials, product portfolios and recent developments. The report also provides information on emerging technologies and the outlook for the investment climate.
Report Synopsis
Report Metrics | Details | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Base year considered | 2022 | ||||||||||||||||
Forecast period considered | 2023-2028 | ||||||||||||||||
Base year market size | $5.8 billion | ||||||||||||||||
Market size forecast | $23.3 billion | ||||||||||||||||
Growth rate | CAGR of 26.4% for the forecast period of 2023-2028 | ||||||||||||||||
Units considered | $ Millions | ||||||||||||||||
Segments covered | Therapy Type, Product Type, Application, and Region | ||||||||||||||||
Regions covered | North America, Europe, Asia-Pacific, and Rest of the World | ||||||||||||||||
Countries covered | U.S., Mexico, Canada, Germany, U.K., France, China, Japan, Australia | ||||||||||||||||
Key Market Drivers |
|
||||||||||||||||
Companies studied |
|
Frequently Asked Questions (FAQs)
- Increasing prevalence of chronic diseases
- Increasing investment in CGT research
- Increasing CGT approvals
- Increasing clinical and commercial manufacturing capacity
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The global market for cell and gene therapy should grow from $4.1 billion in 2021 to $17.4 billion by 2026 with a compound annual growth rate (CAGR) of 33.6% for the period of 2021-2026.
Report Includes
- 20 data tables and 25 additional tables
- An overview of the global market for cell and gene therapy (CGT) products and their applications
- Analyses of the global market trends, with historic data from 2019-2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Evaluation and forecast the overall market size for cell and gene therapy, forecasted growth trends, and corresponding market share analysis by product type, therapy type, application, and region
- Highlights of the upcoming market potential of cell and gene therapy products and areas of focus to forecast this market into various segments and sub-segments
- In-depth information (facts and figures) concerning market drivers, market deterrents and other demographic and economic factors that will drive future demand for this market
- Identification of novel therapeutic products and promising new technologies still in the development and testing stage, and assess the probability that they will be commercialized successfully in the next five years
- Review of emerging companies and the leading competitors in the prevailing cell and gene therapy market, and their global company share analysis
- Impact of COVID-19 pandemic on cell and gene therapy market and related biotech industry
- Review of pipeline analysis and the total number of CGT clinical trials by clinical trial phase, disease indication, and geography
- Descriptive company profiles of the major global players, including Novartis, Orchard Therapeutics plc, Pharmicell Co. Ltd., Sibiono Genetech Co. Ltd., Vericel Corp. and Bristol-Myers Squibb Co.
Related Reports
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Gene Editing Therapeutics Market
The report provides an overview of current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also include company profiles of key players, featuring detailed information regarding each company’s business segments, financials, product portfolios and recent developments.
Synthetic Biology: Global Markets
The global market for synthetic biology products was valued at $15.4 billion in 2023. The market is projected to grow from $19.3 billion in 2024 to $61.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 26.1% from 2024 through 2029.
Global Automated and Closed Cell Therapy Market
The global market for automated and closed cell therapy is expected to grow from $1.8 billion in 2024 and is projected to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.9% during the forecast period of 2024 to 2029.
Recent Reports
Artificial Intelligence (AI) in Cancer
The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Induced Pluripotent Stem Cells: Global Markets
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.
Commercial Amino Acids
The global market for commercial amino acids was valued at $30.1 billion in 2023. It is expected to grow from $31.8 billion in 2024 to $42.8 billion by 2029, at a compound annual growth rate (CAGR) of 6.1% from 2024 through 2029.
Top Trending Reports
AI in Clinical and Molecular Diagnostics Market
The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.
Point-of-Care Diagnostics: Technologies and Global Markets
The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.
Medical Devices: Technologies and Global Markets
The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Global Artificial Intelligence (AI) Market: Investments vs Potential
The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More